• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
WANG Yuhao, ZHANG Xue, ZHOU Xiaoting, HE Hua, LIU Xiaoquan. Pharmacokinetic interaction between sunitinib and ramipril in rats[J]. Journal of China Pharmaceutical University, 2017, 48(1): 60-65. DOI: 10.11665/j.issn.1000-5048.20170109
Citation: WANG Yuhao, ZHANG Xue, ZHOU Xiaoting, HE Hua, LIU Xiaoquan. Pharmacokinetic interaction between sunitinib and ramipril in rats[J]. Journal of China Pharmaceutical University, 2017, 48(1): 60-65. DOI: 10.11665/j.issn.1000-5048.20170109
shu

Pharmacokinetic interaction between sunitinib and ramipril in rats

More Information
    Graphical Abstract
    • Abstract
  • The purpose of this study was to investigate the pharmacokinetic interaction between sunitinib and ramipril in rats. Eighteen male SD rats were divided into three groups, with each group being assigned to orally receive sunitinib, ramipril, sunitinib and ramipril, respectively, for ten days. Blood samples were collected at different times after first-day and tenth-day administration. The concentrations of ramiprilat and sunitinib in rat plasma were determined by LC/MS/MS and the pharmacokinetic parameters were calculated and statistically analyzed. Compared with the administration of ramipril alone, after a single-dose combined administration, tmax of ramiprilat decreased significantly and t1/2 prolonged, while AUC0-∞ remained unchanged. These results indicated that the absorption rate of ramiprilat increased and the elimination rate decreased, but total absorption degree was not changed. After multiple-dose administrations, CL of ramiprilat decreased and AUC0-∞ increased obviously. It suggested that accumulation of ramiprilat occurred in body and the drug elimination became slower. No obvious difference of sunitinib pharmacokinetic behavior was found when it was given in combination with ramipril after a single-dose administration or multiple-dose administration. Sunitinib decreased the elimination of ramiprilat after co-administration in company with drug accumulation in body after multiple-dose co-administration. The study showed that there were pharmacokinetic interactions between sunitinib and ramipril in SD rats.
    • FullText(HTML)
    • References (16)
  • [1]
    Chu TF,Rupnick MA,Kerkela R,et al.Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib[J].Lancet,2007,370(9604):2011-2019.
    [2]
    Kappers MH,Smedts FM,Horn T,et al.The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system[J].Hypertension,2011,58(2):295-302.
    [3]
    Lankhorst S,Kappers MH,van Esch JH,et al.Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib:preclinical study[J].Hypertension,2014,64(6):1282-1289.
    [4]
    Izzedine H,Derosa L,Le Teuff G,et al.Hypertension and angiotensin system inhibitors:impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma[J].Ann Oncol,2015,26(6):1128-1133.
    [5]
    McKay RR, Rodriguez GE, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma[J].Clin Cancer Res,2015,21(11):2471-2479.
    [6]
    Meisel S,Shamiss A,Rosenthal T.Clinical pharmacokinetics of ramipril[J].Clin Pharmacokinet,1994,26(1):7-15.
    [7]
    Franklin PH,Banfor PN,Tapang P,et al.Effect of the multitargeted receptor tyrosine kinase inhibitor,ABT-869[N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N ′-(2-fluoro-5-methylphenyl)urea],on blood pressure in conscious rats and mice:reversal with antihypertensive agents and effect on tumor growth inhibition[J].J Pharmacol Exp Ther,2009,329(3):928-937.
    [8]
    Belcik JT,Qi Y,Kaufmann BA,et al.Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer[J].J Am Coll Cardiol,2012,60(7):618-625.
    [9]
    Yusuf S,Sleight P,Pogue J,et al.Effects of an angiotensin-converting-enzyme inhibitor,ramipril,on cardiovascular events in high-risk patients.The heart outcomes prevention evaluation study investigators[J].N Engl J Med,2000,342(3):145-153.
    [10]
    Li XN,Xu JA,Chen WL,et al.Pharmacokinetics and bioequivalence of domestic and imported ramipril tablets[J].Chin J Clin Pharm(中国临床药学杂志),2009,18(1):9-13.
    [11]
    Scripture CD,Figg WD.Drug interactions in cancer therapy[J].Nat Rev Cancer,2006,6(7):546-558.
    [12]
    Jiang YQ,Tang QF,Zhang S,et al.Combined effects of gallic acid and ciprofloxacin on the murine chronic rhinosinusitis model in mice[J].J China Pharm Univ(中国药科大学学报),2015,46(5):600-604.
    [13]
    Di Gion P,Kanefendt F,Lindauer A,et al.Clinical pharmacokinetics of tyrosine kinase inhibitors:focus on pyrimidines,pyridines and pyrroles[J].Clin Pharmacokineti,2011,50(9):551-603.
    [14]
    Xie SS,Jing XY,Liu XD.Role of intestinal cytochrome P450s in drug metabolism[J].J China Pharm Univ(中国药科大学学报),2010,41(2):186-192.
    [15]
    van Erp NP,Gelderblom H,Guchelaar HJ.Clinical pharmacokinetics of tyrosine kinase inhibitors[J].Cancer Treat Rev,2009,35(8):692-706.
    [16]
    FDA.Drug Databases:Altace(Ramipril).http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019901s065lbl.pdf.
    • Related Articles

  • Related Articles

    [1]ZHANG Ruiqing, YANG Wenqian, YU Yubing, TU Jiasheng, SUN Yixin. Pharmacokinetics of nifedipine matrix sustained-release pellets in rats and the relationship with CYP3A4[J]. Journal of China Pharmaceutical University, 2018, 49(4): 427-432. DOI: 10.11665/j.issn.1000-5048.20180407
    [2]LIANG Yan, XING Rong, LIU Jiali, MAO Yong, FU Hanxu, XIE Lin, WANG Guangji. Advances of novel technologies and theories in pharmacokinetic research[J]. Journal of China Pharmaceutical University, 2014, 45(6): 607-616. DOI: 10.11665/j.issn.1000-5048.20140601
    [3]CHEN Ling-ping, L Wen-li, PING Qi-neng. Preparation and bioavailability of bupropion hydrochloride sustained-release pellets[J]. Journal of China Pharmaceutical University, 2009, 40(5): 421-425.
    [4]DENG Yan-ping, XIAO Yan-yu, PING Qi-neng, GU Xiao-zhen, BAO Quan-ying. Combined system of sinomenine hydrochloride sustained-release pellets[J]. Journal of China Pharmaceutical University, 2009, 40(3): 222-226.
    [5]Pharmacokinetic Study on the Sustained-release Tablets of Labetalol in Dogs[J]. Journal of China Pharmaceutical University, 2003, (6): 48-52.
    [6]Studies on Pharmacokinetics and Bioeqivalence of Aspirin Sustained-Release Pellets[J]. Journal of China Pharmaceutical University, 1993, (6): 334-337.
    [7]Pharmacokinetics and Pharmacodynamics of Sophocarpine and Oxysophocarpine[J]. Journal of China Pharmaceutical University, 1992, (3): 161-164.
    [8]Development of Enteric Aspirin Pellets[J]. Journal of China Pharmaceutical University, 1990, (3): 147-150.
    [9]DEVELOPMENT AND PHARMACOKINETIC STUDY OF SUSTAINED RELEASE IBUPROFEN PELLETS[J]. Journal of China Pharmaceutical University, 1989, (5): 266-270.
    [10]PHARMACOKINETICS OF MATRINR IN RABBITS[J]. Journal of China Pharmaceutical University, 1986, (4): 309-311.

Catalog

    Get Citation
    PDF
    XML
    Article views (1091) PDF downloads (1688) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：309725

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return